\BOOKMARK [1][-]{section.1}{Adapted MARISA model}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{MARISA model}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Adapted MARISA model}{section.1}% 3
\BOOKMARK [1][-]{section.2}{Parameters and rates of the adapted MARISA model}{}% 4
\BOOKMARK [2][-]{subsection.2.1}{Rates related to continuum of care and disease progression}{section.2}% 5
\BOOKMARK [2][-]{subsection.2.2}{Diagnosis, treatment initiation and switching rates}{section.2}% 6
\BOOKMARK [2][-]{subsection.2.3}{Resistance rates}{section.2}% 7
\BOOKMARK [2][-]{subsection.2.4}{Impact of NNRTI-resistance on NNRTI}{section.2}% 8
\BOOKMARK [2][-]{subsection.2.5}{DTG-efficacy and impact of NRTI-resistance on DTG}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.6}{Other parameters: HIV transmission and mortality}{section.2}% 10
\BOOKMARK [1][-]{section.3}{Model simulation}{}% 11
\BOOKMARK [2][-]{subsection.3.1}{Prospective scenarios}{section.3}% 12
\BOOKMARK [2][-]{subsection.3.2}{Sensitivity analysis}{section.3}% 13
\BOOKMARK [1][-]{section.4}{Model ODEs}{}% 14
\BOOKMARK [2][-]{subsection.4.1}{Description of the compartments}{section.4}% 15
\BOOKMARK [2][-]{subsection.4.2}{Model ODEs}{section.4}% 16
\BOOKMARK [1][-]{section.5}{Sensitivity analysis and additional results}{}% 17
\BOOKMARK [2][-]{subsection.5.1}{Effect of no Treat-All policy}{section.5}% 18
\BOOKMARK [2][-]{subsection.5.2}{Effect of treatment interruption}{section.5}% 19
\BOOKMARK [2][-]{subsection.5.3}{Effect of NRTI-resistance and higher efficacy of DTG}{section.5}% 20
